NEXT Oncology, an Avacare business, strives to provide exceptional care, the latest cancer treatments, and a community devoted to finding a cure.
11/05/2025
We are delighted to announce our expansion to Osaka, J*pan in collaboration with Dr. Toshio Shimizu and Kansai Medical University.
Read more:
With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. [SAN ANTONIO, TX – November 5, 2025] NEXT Oncology, an Avacare business, has expanded its services to Asia through a strategic partnership with Kansai Medical University in Osaka, J*p...
10/24/2025
We were proud to join our colleagues and collaborators at the SPARC Summit—an inspiring forum hosted by Bayer that brought together leaders in early-phase oncology research.
NEXT Oncology is honored to be working with Bayer across five different Phase I trials, advancing innovative cancer therapies through global collaboration. Events like this reflect the shared commitment to accelerating progress in oncology through partnership and scientific exchange.
A big thank you to the Bayer team and all who participated in this impactful event.
hashtag hashtag hashtag hashtag hashtag
09/11/2025
Congratulations to our colleagues at Revolution Medicines on these groundbreaking trials. We are proud to work with you.
We are happy to welcome Faran S Polani, MD to the NEXT Oncology team in our Dallas office!
08/27/2025
Don't miss this learning opportunity at the 2025 Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer), featuring Anthony Tolcher and Shiraj Sen!
ICYMI:We’re proud to announce that results from a Phase 1 clinical trial led by Ildefonso Rodriguez-Rivera have been published in Nature Medicine. The study evaluated precemtabart tocentecan (precem-TcT) in collaboration with EMD Serono, Inc. in patients with metastatic colorectal cancer and showed encouraging early activity and manageable safety.
This publication reflects our continued commitment to advancing first-in-human cancer research and improving outcomes for patients with limited treatment options.
Phase 1 trial findings published in Nature Medicine show promise for a new approach to targeting colorectal cancer and other tumors expressing CEACAM5. NEXT Oncology’s Dr. Ildefonso Ismael Rodriguez Rivera, a medical oncologist and hematologist in the San Antonio office, has led an innovative Phas...
08/07/2025
We’re proud to announce that results from a Phase 1 clinical trial led by Ildefonso Rodriguez-Rivera have been published in Nature Medicine. The study evaluated precemtabart tocentecan (precem-TcT) in collaboration with EMD Serono, Inc. in patients with metastatic colorectal cancer and showed encouraging early activity and manageable safety.
This publication reflects our continued commitment to advancing first-in-human cancer research and improving outcomes for patients with limited treatment options.
We were thrilled to celebrate the opening of our newest location in Houston with a fun Grand Opening party.
06/09/2025
Congratulations to our colleagues at Iambic Therapeutics for continued success. Our own Andrae Vandross with NEXT - Austin had this to say: “Patients entering this study, particularly those with brain metastases, have few available treatment options. Our focus is on identifying important potential advances for these individuals and to look at novel approaches that may provide a therapeutic benefit.”
Read more here:
Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment
06/02/2025
We are very honored to support ongoing clinical research at American Society of Clinical Oncology (ASCO) 2025 and the Merit awards. Congratulations to Curtis Perry, recipient of the Anthony and Marilyn Tolcher Merit award and Udhayvia Grewal, recipient of the Theresa Mays Endowed Merit Award, for their outstanding work.
Be the first to know and let us send you an email when NEXT Oncology, an Avacare business posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Contact The Practice
Send a message to NEXT Oncology, an Avacare business:
Our mission is to transform the industry though the development of the next breakthrough in cancer research through high quality Phase 1 clinical pharmacology trials.
NEXT Oncology, founded by Anthony W. Tolcher, M.D., FRCPC, is a Phase 1 center dedicated to providing options for advanced cancer patients and advancing cancer research. Dr. Tolcher’s passion for research and the community lays the foundation for an international brand committed to finding the next breakthrough.
Dr. Anthony Tolcher is a medical oncologist and co-founder of NEXT. He is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option that includes clinical trials of new agents and therapies. Dr. Tolcher is proud that at NEXT Oncology the team scours the world to bring the best new agents back to our patients and centers.
This is not a job for Dr. Tolcher, it is his passion.
"We are going to make cancer treatable or curable in my lifetime." Read more from Dr. Tolcher in the recent article written by WOAI.
